Hypoxia-inducible factor (HIF) signaling represents a promising neuroprotective approach for Parkinson's disease. Companies are developing prolyl hydroxylase inhibitors (PHIs) that stabilize HIF-α subunits, activating protective gene programs including VEGF, erythropoietin (EPO), BNIP3, and glycolytic enzymes. This approach addresses the "pseudo-hypoxic state" created by mitochondrial complex I dysfunction in PD dopaminergic neurons.
This category covers companies developing HIF-targeting therapeutics for PD, including clinically approved PHD inhibitors being repurposed for neurodegeneration and novel brain-penetrant compounds in development.
Mechanism: Oral prolyl hydroxylase inhibitor (PHD1-3)
Clinical Stage: Phase II (AD/PD)
Background: Akros Pharma is advancing vadadustat, an oral PHD inhibitor originally developed for anemia of chronic kidney disease, for CNS applications. The company has initiated Phase II trials in Alzheimer's disease and is exploring Parkinson's disease indications. Preclinical data demonstrate that vadadustat crosses the blood-brain barrier and provides neuroprotection in MPTP and 6-OHDA models of PD[@akros2024].
Key Science:
Clinical Development:
Mechanism: Oral prolyl hydroxylase inhibitor (PHD1-3)
Clinical Stage: Approved for anemia (CKD); preclinical for PD
Background: Roxadustat (FG-4592) is approved in multiple countries for anemia associated with chronic kidney disease. FibroGen and partner Astellas are exploring CNS applications. Roxadustat has demonstrated neuroprotective effects in multiple preclinical PD models, including MPTP-induced dopaminergic toxicity and 6-OHDA lesions[@fibrogen2024].
Key Science:
Development Status:
Mechanism: Brain-penetrant prolyl hydroxylase inhibitor
Clinical Stage: Preclinical (CNS)
Background: Daiichi Sankyo is developing DS-1090, a PHD inhibitor specifically optimized for CNS penetration. The company has modified the roxadustat scaffold to enhance blood-brain barrier crossing. Preclinical studies show superior brain exposure compared to first-generation PHD inhibitors with maintained PHD inhibition potency[@daiichi2024].
Key Science:
Development Status:
Mechanism: HIF-1α direct stabilizer (non-PHD mechanism)
Clinical Stage: Preclinical
Background: Avid Bioservices is developing AKB-6899, a direct HIF-1α stabilizer that bypasses PHD inhibition. This approach may offer more selective HIF-1α activation without affecting PHD enzymes involved in other cellular processes. Preclinical data show neuroprotection in oxidative stress models relevant to PD[@avid2024].
Key Science:
Development Status:
Mechanism: Isoform-selective PHD inhibitors
Clinical Stage: Discovery/Preclinical
Background: Restartis Therapeutics is developing next-generation PHD inhibitors with selectivity for specific PHD isoforms (PHD1 vs. PHD2 vs. PHD3). Different isoforms may have distinct roles in neuronal survival, with PHD2 inhibition being particularly relevant for neuroprotection. The company aims to develop compounds with improved therapeutic index[@restartis2024].
Key Science:
Development Status:
Mechanism: AAV-mediated HIF-1α gene therapy
Clinical Stage: Preclinical
Background: Cerebral Therapeutics is developing AAV-delivered HIF-1α constructs for sustained HIF activation in the brain. Unlike small molecule approaches requiring chronic dosing, gene therapy could provide long-term HIF stabilization. The company is targeting PD and other neurodegenerative conditions[@cerebral2024].
Key Science:
Development Status:
| Institution | Approach | Status |
|---|---|---|
| NIH/NINDS | PHD inhibitor repurposing program | Preclinical |
| Stanford University | HIF-1α gene therapy | Preclinical |
| University of Pennsylvania | BNIP3-targeted approaches | Research |
| UCL Queen Square | Hypoxic preconditioning protocols | Clinical (repurposed) |
The HIF pathway is particularly relevant for PD because:
| Company | Compound | Mechanism | Stage | Target Indication |
|---|---|---|---|---|
| Akros Pharma | Vadadustat | PHD inhibitor | Phase II | AD/PD |
| FibroGen/Astellas | Roxadustat | PHD inhibitor | Preclinical | PD |
| Daiichi Sankyo | DS-1090 | Brain-penetrant PHDi | Preclinical | AD/PD |
| Avid Bioservices | AKB-6899 | Direct HIF-1α stab. | Preclinical | PD |
| Restartis | Novel PHDi | Isoform-selective | Discovery | ALS/PD |
| Cerebral Therapeutics | AAV-HIF | Gene therapy | Preclinical | PD |
| Challenge | Mitigation |
|---|---|
| Chronic vs. acute timing | Precise dosing protocols, biomarkers |
| Polycythemia risk | Brain-penetrant compounds, isoform selectivity |
| Tumor promotion concerns | Limited duration, patient monitoring |
| BBB penetration | Structural modifications, alternate delivery |
| Biomarker development | HIF target gene expression monitoring |